



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



**Date: 13 February 2024**

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: RECORDING OF THE EARNINGS CONFERENCE CALL ON THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER 2023**

Dear Sir/Madam,

In accordance with the applicable requirements and regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable Regulations, we hereby inform you that the Recording of the Earnings Conference Call in connection with the Unaudited Consolidated and Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2023, held on February 13, 2024, is available on the website of the Company and can be accessed through the following link:

Link: <https://eris.co.in/financials/>

(File name: Q3 FY24-Earnings Call Recording)

Thanking You,

**For Eris Lifesciences Limited**

\_\_\_\_\_  
**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**  
**ICSI Mem. No.: A26493**

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867